UroGen Pharma Ltd. (URGN) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
URGN Revenue Growth
Revenue Breakdown (FY 2025)
URGN's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
URGN Revenue Analysis (2014–2025)
As of May 8, 2026, UroGen Pharma Ltd. (URGN) generated trailing twelve-month (TTM) revenue of $140.5 million, reflecting explosive growth of +151.6% year-over-year. The most recent quarter (Q1 2026) recorded $51.0 million in revenue, up 34.7% sequentially.
Looking at the longer-term picture, URGN's 5-year compound annual growth rate (CAGR) stands at +56.2%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $109.8 million in 2025, representing a new all-time high.
Revenue diversification analysis shows URGN's business is primarily driven by Jelmyto (100%). With over half of revenue concentrated in Jelmyto, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including SUPN (+16.3% YoY), PRGO (-3.6% YoY), and PAHC (+32.4% YoY), URGN has outperformed the peer group in terms of revenue growth. Compare URGN vs SUPN →
URGN Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| URGNCurrent | $140M | +151.6% | +56.2% | -113.7% | |
 SUPN | $719M | +16.3% | +6.7% | -5.1% | |
 PRGO | $4.3B | -3.6% | +0.8% | 8.1% | |
 PAHC | $1.3B | +32.4% | +10.1% | 8.5% |
URGN Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $109.8M | +21.4% | $97.3M | 88.7% | $-124,863,000 | -113.7% |
| 2024 | $90.4M | +9.3% | $81.5M | 90.2% | $-96,782,000 | -107.1% |
| 2023 | $82.7M | +28.5% | $73.4M | 88.7% | $-65,536,000 | -79.2% |
| 2022 | $64.4M | +34.0% | $56.7M | 88.1% | $-79,041,000 | -122.8% |
| 2021 | $48.0M | +307.2% | $42.9M | 89.3% | $-92,292,000 | -192.1% |
| 2020 | $11.8M | +65450.0% | $10.8M | 91.4% | $-126,739,000 | -1074.2% |
| 2019 | $18K | -98.4% | $18K | 100.0% | $-109,478,000 | -608211.1% |
| 2018 | $1.1M | -86.2% | $-675,000 | -59.8% | $-77,180,000 | -6842.2% |
| 2017 | $8.2M | -53.5% | $7.6M | 92.6% | $-19,950,000 | -244.5% |
| 2016 | $17.5M | - | $17.5M | 99.8% | $798K | 4.6% |
See URGN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs URGN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare URGN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonURGN — Frequently Asked Questions
Quick answers to the most common questions about buying URGN stock.
Is URGN's revenue growth accelerating or slowing?
URGN revenue is accelerating at +151.6% year-over-year, exceeding the 5-year CAGR of +56.2%. TTM revenue reached $140M. Growth momentum has increased versus prior periods.
What is URGN's long-term revenue growth rate?
UroGen Pharma Ltd.'s 5-year revenue CAGR of +56.2% reflects the sustained expansion pattern. Current YoY growth of +151.6% is above this long-term average.
How is URGN's revenue distributed by segment?
URGN reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.